

Special Issue

Feature Papers in Cancer Biology and Anticancer Therapeutics

Message from the Guest Editor

Cancer is a complex disease involving genetic/epigenetic alterations and multiple pathogenetic mechanisms. Investigation of the differential characteristics of various types of cancer cells, which distinguish them from normal cells, allows for the identification of cancer-specific targets. The principle of cancer chemo- and immune-therapies is based on the molecular targeting of the vulnerabilities of cancer cells inducing cell death by apoptosis. In this Special Issue, we focus attention on novel target-based anticancer agents and therapeutics that exploit the vulnerabilities of cancer cells. We welcome the submission of research and review articles on the development of new anticancer agents and therapeutics.


Guest Editor

Prof. Dr. Seiichi Tanuma

1. Department of Genomic Medicinal Science, Research Institute for Science and Technology, Organization for Research Advancement, Tokyo University of Science, Noda, Chiba 278-8510, Japan
2. Department of Biochemistry, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Chiba 278-8510, Japan

Deadline for manuscript submissions

closed (31 May 2021)



Medicines

an Open Access Journal
by MDPI

Indexed in PubMed




mdpi.com/si/65901

Medicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
medicines@mdpi.com

[mdpi.com/journal/
medicines](https://mdpi.com/journal/medicines)





Medicines

an Open Access Journal
by MDPI

Indexed in PubMed



[mdpi.com/journal/
medicines](https://mdpi.com/journal/medicines)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Hiroshi Sakagami
Meikai University Research Institute of Odontology (M-RIO), 1-1
Keyakidai, Sakado, Saitama 350-0283, Japan

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within PubMed, PMC, CAPlus / SciFinder, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 45 days after submission; acceptance to publication is undertaken in 5.7 days (median values for papers published in this journal in the first half of 2025).